AbbVie accuses rival of stealing blockbuster ‘trade secrets’ as clock ticks down on biosimilar assault
Two years before the first biosimilars to megablockbuster Humira are expected to hit the US market, AbbVie is taking one developer to court over allegations it stole trade secrets to create its copycat version.
AbbVie has filed suit against Icelandic biotech Alvotech for “injunctive relief and recovery of damages,” according to court documents dated Friday. The pharma accuses Alvotech of embarking on an “unlawful plot to surreptitiously take AbbVie’s confidential and proprietary trade secrets.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.